Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,528.52
(
2.91%
)
US TECH 100
23,161.07
(
3.72%
)
Dow Jones
46,341.51
(
2.49%
)
Brent Oil
104.86
(
1.66%
)
Bitcoin
67,618.93
(
-0.95%
)
News Focus
News Focus
Post# of 257323
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122830
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 182630

Monday, 12/01/2014 8:57:22 AM

Monday, December 01, 2014 8:57:22 AM

Post# of 257323
MNTA/BAX—CTA for M923 (Humira FoB) accepted by UK, triggering $12M milestone payment from BAX to MNTA and allowing a phase-1 trial of M923 to start immediately:

http://finance.yahoo.com/news/momenta-pharmaceuticals-announces-acceptance-clinical-130000081.html

Nuance: Today’s PR says MNTA expects to receive the $12M in 4Q14; prior guidance was for receipt in 4Q14 or 1Q15.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now